Company Description
Sotera Health Co. provides mission-critical sterilization, lab testing and advisory services to the medical device and pharmaceutical industries. It also provides end-to-end sterilization as well as microbiological and analytical lab testing and advisory services to help ensure that medical, pharmac...
Sotera Health Co. provides mission-critical sterilization, lab testing and advisory services to the medical device and pharmaceutical industries. It also provides end-to-end sterilization as well as microbiological and analytical lab testing and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients and consumers. The firm operates through the following businesses: Sterigenics, Nordion, and Nelson Labs. The Sterigenics business provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets by using following technologies: gamma irradiation, EO processing and E-beam irradiation. The Nordion business provides Co-60 and gamma irradiators, which are the key components to the gamma sterilization process. The Nelson Labs business provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. The company was founded in 1978 and is headquartered in Broadview Heights, OH.
Valuation
P/E Current
45.24
P/E Ratio (with extraordinary items)
43.31
P/E Ratio (without extraordinary items)
57.04
Price to Sales Ratio
7.06
Price to Book Ratio
11.37
Price to Cash Flow Ratio
23.95
Enterprise Value to EBITDA
15.41
Enterprise Value to Sales
7.04
Efficiency
Total Asset Turnover
0.34
Liquidity
Current Ratio
2.15
Quick Ratio
1.79
Cash Ratio
0.66
Profitability
Gross Margin
48.84
Operating Margin
32.25
Pretax Margin
18.86
Net Margin
12.38
Return on Assets
4.16
Return on Equity
22.22
Return on Total Capital
12.54
Capital Structure
Total Debt to Total Assets
65.53
Officers and Executives
Name | Age | Officer Since | Title |
---|---|---|---|
Mr. Michael B. Petras | 52 | 2016 | Chairman & Chief Executive Officer |
Mr. Michael Francis Biehl | 65 | 2022 | Chief Financial Officer |
Mr. Robert G. Hauzie | - | 2019 | Chief Information Officer |
Mr. Michael P. Rutz | 48 | 2020 | President-Sterigenics |
Mr. Kurt M. Roth | - | 2015 | Senior VP-Corporate Development & Strategy |
Insider Actions
11/20/2022 |
Michael B. Petras Chairman & CEO; Director |
29,251 | Derivative/Non-derivative trans. at $6.02 per share. | 176,091 |
11/20/2022 |
Michael P. Rutz President of Sterigenics |
1,911 | Derivative/Non-derivative trans. at $6.02 per share. | 11,504 |
11/07/2022 |
Alexander Dimitrief SVP, General Counsel and Sec. |
235,478 | Award at $0 per share. | 0 |
05/27/2022 |
Ann R. Klee Director |
10,643 | Award at $0 per share. | 0 |
05/27/2022 |
Vincent Kevin Petrella Director |
10,643 | Award at $0 per share. | 0 |
05/27/2022 |
Dave Anthony Donnini Director |
10,643 | Award at $0 per share. | 0 |
05/27/2022 |
Dean Spyro Mihas Director |
10,643 | Award at $0 per share. | 0 |
05/27/2022 |
Sean Laurence Cunningham Director |
10,643 | Award at $0 per share. | 0 |
05/27/2022 |
James C. Neary Director |
10,643 | Award at $0 per share. | 0 |
05/27/2022 |
Ruoxi Chen Director |
10,643 | Award at $0 per share. | 0 |
05/27/2022 |
Stephanie M. Geveda Director |
10,643 | Award at $0 per share. | 0 |
05/27/2022 |
David E. Wheadon Director |
10,643 | Award at $0 per share. | 0 |
03/02/2022 |
Michael B. Petras Chairman & CEO; Director |
187,219 | Award at $0 per share. | 0 |
03/02/2022 |
Scott J. Leffler CFO and Treasurer |
37,443 | Award at $0 per share. | 0 |
03/02/2022 |
Michael P. Rutz President of Sterigenics |
24,962 | Award at $0 per share. | 0 |
03/02/2022 |
Terrence G. Hammons SVP, GC and Secretary |
22,466 | Award at $0 per share. | 0 |
11/20/2021 |
Michael B. Petras Chairman & CEO; Director |
27,517 | Derivative/Non-derivative trans. at $22.54 per share. | 620,233 |
11/20/2021 |
Scott J. Leffler CFO and Treasurer |
3,894 | Derivative/Non-derivative trans. at $22.54 per share. | 87,770 |
11/20/2021 |
Michael P. Rutz President of Sterigenics |
1,911 | Derivative/Non-derivative trans. at $22.54 per share. | 43,073 |
11/11/2021 |
Terrence G. Hammons SVP, GC and Secretary |
8,791 | Award at $0 per share. | 0 |
08/25/2021 |
Michael P. Rutz President of Sterigenics |
67,000 | Disposition at $25.03 per share. | 1,677,010 |
05/28/2021 |
Ann R. Klee Director |
9,336 | Award at $0 per share. | 0 |
05/28/2021 |
Vincent Kevin Petrella Director |
9,336 | Award at $0 per share. | 0 |
05/28/2021 |
Dave Anthony Donnini Director |
9,336 | Award at $0 per share. | 0 |
05/28/2021 |
Dean Spyro Mihas Director |
9,336 | Award at $0 per share. | 0 |
05/28/2021 |
Sean Laurence Cunningham Director |
9,336 | Award at $0 per share. | 0 |
05/28/2021 |
James C. Neary Director |
9,336 | Award at $0 per share. | 0 |
05/28/2021 |
Ruoxi Chen Director |
9,336 | Award at $0 per share. | 0 |
05/28/2021 |
Stephanie M. Geveda Director |
9,336 | Award at $0 per share. | 0 |
05/28/2021 |
David E. Wheadon Director |
9,336 | Award at $0 per share. | 0 |
03/22/2021 |
Warburg Pincus LLC Director |
13,512,582 | Disposition at $26.12 per share. | 352,948,641 |
03/22/2021 |
Warburg Pincus LLC Director |
13,512,582 | Disposition at $26.12 per share. | 352,948,641 |
03/22/2021 |
GTCR LLC Director |
9,008,388 | Disposition at $26.12 per share. | 235,299,094 |
03/22/2021 |
Michael B. Petras Chairman & CEO; Director |
817,439 | Disposition at $26.12 per share. | 21,351,506 |
03/22/2021 |
Matthew J. Klaben Interim SVP, GC and Secretary |
41,952 | Disposition at $26.12 per share. | 1,095,786 |
11/24/2020 |
Michael B. Petras Chairman & CEO; Director |
946,102 | 20,511,491 | |
11/24/2020 |
Michael B. Petras Chairman & CEO; Director |
437,821 | 9,491,959 | |
11/24/2020 |
Scott J. Leffler CFO and Treasurer |
115,326 | 2,500,267 | |
11/24/2020 |
Matthew J. Klaben Interim SVP, GC and Secretary |
69,196 | 1,500,169 |
MarketWatch News on SHC
-
Sotera Health upgraded to neutral from underweight at J.P. Morgan
- Tomi Kilgore
-
Compass Pitches 5% Yield Today, Growth Tomorrow
- Barron's Online
-
Compass Has a Growth Pitch but Investors Are Wary
- Barron's Online
-
Sotera Health downgraded to sector weight from overweight at KeyBanc Capital
- Tomi Kilgore
-
Sotera Health double downgraded to underweight from overweight at J.P. Morgan
- Tomi Kilgore
-
Inflation Ran Hot in December. 15 Stocks to Help Tame It.
- Barron's Online
-
Sotera Health started at overweight with $35 stock price target at J.P. Morgan
- Tomi Kilgore
-
Stocks end the week on a downbeat as rising COVID cases weigh
- Mark DeCambre
-
Maravai LifeSciences Jumps Nearly 19% in IPO. Sotera Pops 17%.
- Barron's Online
-
Sotera Health's stock opens at $27.00, or 17% above IPO price
- Tomi Kilgore
-
Sotera Health's stock now indicated to open around $26.15, or 13.7% above the IPO price
- Tomi Kilgore
-
Sotera Health's stock indicated to open around $25.20, or 9.6% above the $23 IPO price
- Tomi Kilgore
-
Sotera Health sets IPO terms, to offer 46.6 mln shares priced at $20 to $23 each
- Ciara Linnane
Other News on SHC
-
Sotera Health Company (SHC) Q3 2022 Earnings Call Transcript
- Seeking Alpha
-
- Edgar Online - (EDG = 10Q, 10K)
-
Sotera Health: Litigation Looms Large
- Seeking Alpha
-
The 1-Minute Market Report October 2, 2022
- Seeking Alpha
-
Warning: SHC is at high risk of performing badly
- Seeking Alpha
-
Why Sotera Health Stock Tumbled Again on Tuesday
- Motley Fool
-
BLUE, TUSK and TRVI among mid-day movers
- Seeking Alpha
-
Why Sotera Health Stock Crumbled Today
- Motley Fool
-
Warburg Pincus Partner Stephanie Geveda to Launch New Firm
- The Wall Street Journal Interactive Edition
- Loading more headlines...